Biological Industries is now part of the Sartorius group. Click here for more


Biological Industries USA Adds Strategic Offering of
Small Molecules to its Stem Cell Portfolio

August 8, 2019 -- CROMWELL, Conn. -- Biological Industries USA (BI-USA), a division of Biological Industries Beit Haemek Israel (BI), and provider of cell culture tools for translational research, today announced the addition and sale of small molecules for stem cell applications; specifically for enhancing research in diabetes, neural disorders, and cardiovascular disease.

Small molecules can be used to modulate biological signals for a multitude of applications, including cellular reprogramming, stem cell self-renewal, and the differentiation of stem cells into specific lineages, altogether advancing the rapidly evolving field of translational cell therapy. BI-USA hopes to continue supporting innovative growth in this setting by expanding their comprehensive stem cell portfolio with cost-effective small molecule products. When altering cellular circuitry with these small molecules, BI’s family of NutriStem® hPSC Media offers a clean and streamlined base medium for more efficient downstream processing. Today’s announcement thus adds a key asset to the extensive BI-USA portfolio of stem cell culture solutions, especially for those focusing on the aforementioned specialized areas of research.

“With the launch of our small molecules, researchers who use our xeno-free, serum-free stem cell media now have access to a very specific and strategic portfolio of high-quality small molecules to aid in the differentiation of specific cell types. Launching this portfolio is the first step in helping our customers get access to key products in their workflow at extremely low prices.” said Tanya Potcova, CEO of Biological Industries USA.

For more information about BI’s strategic portfolio of small molecules or NutriStem® hPSC Medium, please visit

About Biological Industries (BI)
Biological Industries ( is one of the world’s leading and trusted suppliers to the life sciences industry, with over 35 years’ experience in cell culture media development and GMP manufacturing. BI’s products range from classical cell culture media, to supplements and reagents for stem cell research and cell therapy applications, to serum and serum-free media products. Services offered also include complete customization of media, reagents, and packaging to fulfill the needs of any cell culture workflow. BI is committed to a Culture of Excellence through advanced manufacturing and quality-control systems, regulatory expertise, in-depth market knowledge, and extensive technical customer-support, training, and R&D capabilities.

About Biological Industries USA (BI-USA)
Biological Industries USA ( is the US commercialization arm of BI, with facilities in Cromwell, Connecticut. Members of the BI-USA team share expertise and a history of innovation and success in the development of leading-edge technologies in stem cell research, cellular reprogramming, and regenerative medicine.

To receive ongoing BI communications, please join our email list or connect with the company at or via LinkedIn, Twitter, and Facebook.

Michelle Janaszak, Marketing Manager